ArticleBiochemistry and biophysics reports2026
Overexpression of DYRK1A in down syndrome: Analysis of kinase activity.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DYRK1A (dual-specificity tyrosine phosphorylation regulated kinase 1A) is known to play critical roles in regulating numerous cellular functions like cell cycle, neuronal development, and immune homeostasis. Altered expression DYRK1A is implicated in Alzheimer's Disease and various features of Down Syndrome (DS). The DYRK1A gene is located on chromosome 21 and due to trisomy of this chromosome in DS, the level of DYRK1A is elevated in the gene-dosage dependent manner. Nevertheless, how an increase in DYRK1A protein level would affect its activity in DS remains to be determined. The question was examined by performing side by side comparison of protein levels and the activity of DYRK1A extracted from control and DS samples. We show that DYRK1A activity elevation in DS is in parallel to that of DYRK1A protein level regardless of the status of kinase phosphorylation. This suggests that DYRK1A catalytic activity in DS is mainly regulated by protein level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.